Introduction
Mitral annular calcification (MAC) is a chronic degenerative process of the fibrous support structure of the mitral valve. 1 The reported prevalence of MAC in the general population is between 8% and 15%, but it significantly increases with age and in patients with multiple cardiovascular risk factors, chronic renal failure, or aortic stenosis (AS). [1] [2] [3] There is growing evidence that identification of calcified mitral annulus can be related independently to higher risk of cardiovascular events, conduction abnormalities, mitral valve disease, and mortality. 1, [4] [5] [6] [7] Previously, echocardiography was considered the best method to demonstrate MAC, but cardiac computed tomography (CT) is superior for evaluating the extent and location of MAC and for quantifying MAC objectively in order to assess its severity. 1, 8 Calcified AS and MAC have certain similar etiology and pathophysiological mechanisms. 1 Both conditions may be initiated by endothelial injury at foci of increased mechanical stress and progress to an atherosclerotic calcification. 9 They are, therefore, observed most commonly in the presence of significant atherosclerosis in the elderly.
Transcatheter aortic valve replacement (TAVR) has emerged as a treatment option for inoperable or high-risk surgical patients with severe AS. 10, 11 During recent years, there has been a substantial increase in the utilization of cardiac CT of patients with severe AS being evaluated for TAVR 12 . MAC is frequently encountered in these CT examinations but its prognostic implication in these patients has not been thoroughly investigated.
In our study, we sought to evaluate the prevalence of MAC among a large cohort of patients with severe AS and to assess the clinical implications of MAC on patients being treated with TAVR.
Methods
We retrospectively examined 761 patients with severe symptomatic AS that underwent TAVR during a three year period at the Cedars-Sinai Heart Institute. The study was approved by the institutional review board (IRB) and informed consent was obtained from all subjects. All patients had congestive heart failure with New-York Heart Association (NYHA) class II-IV symptoms. They underwent pre-procedural coronary angiography to assess the need for revascularization. Aortic valve disease was assessed with transthoracic echocardiography performed by experienced echocardiographers. Evaluation of AS severity was performed based on peak velocity, mean gradient, and calculation of the aortic valve area (AVA) using the continuity equation as recommended by current guidelines. 13 All patients had an AVA of <1 cm 2 and indexed AVA (AVA/body surface area) of <0.6 cm 2 /m 2 . Mitral regurgitation (MR) was evaluated pre-and post-TAVR on the basis of the integration of color Doppler jet area, vena contracta, and proximal isovelocity surface area and graded as no/trivial, mild, moderate, or severe. 14 Mitral valve gradients were determined from the Doppler diastolic mitral flow and considered significant if the mean gradient was > _5 mmHg. 15 Patients were also evaluated by an ECG-gated, multi-slice CT angiography study using a second-generation dual-source CT system (Siemens SOMATOM Definition Flash; Siemens Healthcare, Erlangen, Germany). Acquisition was in the cranio-caudal direction from the aortic arch to the diaphragm. CT was performed with a collimation of 128 Â 0.625 mm and maximum tube current ranged was automated for each patient using Caredose (Siemens Healthcare, Erlangen, Germany) with a fixed tube potential of 100-120 kV. Images were reconstructed at 0.6 mm slices with 0.3 mm overlap with iterative reconstruction for evaluation at 10% intervals within the 0-90% RR range. CT images were reconstructed using 3mensio Valves Version 7.0 or 7.1 (3mensio Medical Imaging BV, Bilthoven, The Netherlands). Several views including axial and double oblique view at the mitral annular level as well as maximal intensity projection (MIP) reconstruction were used to assess the presence of MAC and its severity. MAC was defined by presence of dense calcium deposits at the base of mitral leaflets between the left atrium and ventricle. MAC severity was qualitatively determined by the circumferential involvement of the mitral ring 5, 16 : mild = less than 1/3 of the annulus involved; moderate = between 1/3 and 1 =2; and severe = calcification in more than half of the mitral annulus circumference (Figure 1) . From a repeated measurement for a subset of 25 randomly selected patients, intra-and interobserver variability for MAC severity grading was satisfactory (intra-observer: intra-class correlation coefficient: 0.97, P < 0.001; inter-observer: intra-class correlation coefficient: 0.94, P < 0.001). MAC was also quantified using 3mensio Valves software with threshold of 850 Hounsfield Units (HU) used to detect areas of calcium in the region of interest as previously validated in our institute for aortic valve calcium quantification in TAVR patients. 17 Maximal calcification thickness was also measured.
Left ventricular outflow tract (LVOT) calcification was defined as any calcification between the aortic valve annulus plane and 5 mm inferior to this plane. This was performed by one of the physician readers experienced in the assessment of pre-TAVR CT scans, blinded to the clinical data. Aortic valve calcium was quantified by a standard Agatston methodology for all available non-contrast CT scans, with a threshold for calcium detection set at 130 HU and 3-mm slice thickness. 18 All patients were considered high-risk for valve surgery by our institutional heart team. Prosthetic valve size selection was based on CT or immediate pre-procedural three-dimensional transesophageal echocardiography. TAVR was performed under general anesthesia in all cases. The vascular access approach was chosen on the basis of the individual patient's risk profile. Baseline clinical, echocardiographic and procedural details for TAVR were recorded for all patients including 1 month clinical and echocardiographic evaluation during a followup visit. TAVR endpoints, device success, and adverse events were recorded using the Valve Academic Research Consortium (VARC)-2 definitions. 19 Post-TAVR paravalvular regurgitation (PVR) was assessed in line with VARC-2 criteria with peri-procedural transesophageal echocardiography examinations reviewed retrospectively.
Statistical analysis
Continuous variables were tested for distribution normality with the Shapiro-Wilk test and expressed as mean ± SD or median and interquartile range. These variables were compared using two- 
calcification, and MAC. A multivariable logistic regression analysis was performed to assess independent predictors of 1-year all-cause and cardiovascular mortality in patients that underwent TAVR. This multivariable model was built by selecting variables that satisfied the entry criterion of P < 0.1 in a univariate 1-year mortality analysis: body mass index, chronic lung disease, peripheral artery disease, frailty, chronic renal failure, alternative access, STS score, left ventricular ejection fraction, and MAC. In order to assess predictors of new permanent pacemaker implantation (PPI) we performed a logistic regression analysis including baseline atrial fibrillation, post-dilatation (balloon aortic valvuloplasty following valve deployment), left bundle branch block, right bundle branch block, MAC, LVOT calcification, aortic valve calcification, valve type (self-expandable vs. balloon expandable), and valve size (23 mm/26 mm vs. 29 mm/31 mm). Patients who had PPI before TAVR were excluded from this analysis. This model was evaluated using Hosmer-Lemeshow goodness of fit test and C-statistics. All of the analyses were considered significant at a two-tailed P value of less than 0.05. The SPSS statistical package, version 20 .0 was used to perform all statistical evaluation (SSPS Inc. Chicago, IL, USA).
Results
Overall, 761 out of 782 patients with severe AS that underwent TAVR at our institution during the study period had pre-TAVR CT 
Baseline characteristics
The baseline clinical patient characteristics and pre-TAVR imaging details of the study population are shown in Table 1 . The average age was 81.2 ± 9.0 for patients with no MAC compared to 83.0 ± 8.5 for patients with MAC (P = 0.004). Patients with no MAC had male predominance (70.2%), compared with 1:1 male:female ratio among patients with MAC (P < 0.001). Chronic renal failure was more prevalent in patients with MAC (21.9% vs. 14.2%; P = 0.01). Patients with severe MAC had similar chronic renal failure prevalence as patient with no MAC (13.9%). The STS score was significantly higher for patients with MAC (8.8 ± 5.7 vs. 7.5 ± 4.3; P < 0.001). The MAC group had significantly higher baseline left ventricular ejection fraction, and higher aortic valve mean/peak echo gradients (59.5% and 46.7/77.9 mmHg vs. 54.3% and 44.3/74.6 mmHg, respectively; P < 0.05 for all). Baseline MR grades were similar between both groups ( Table 1) . CT scan analysis demonstrated significantly higher prevalence of LVOT calcification (51.2% vs. 39.9%; P = 0.002) and lower mean annulus diameter and area for patients with MAC. The mean MAC volume with HU-850 threshold was 117 ± 107 mm 3 , 532± 245 mm 3 , and 2247 ± 1520 mm 3 for the mild, 
moderate, and severe MAC groups, respectively (P < 0.001). The mean MAC maximal thickness was 5.1 ± 1.9 mm, 7.7 ± 1.7 mm, and 11.4 ± 3.6 mm for the mild, moderate, and severe MAC groups, respectively (P < 0.001).
Procedural details
Procedural details are shown in Table 2 . Overall, the transfemoral approach was used in 86.6% of the cases, transapical approach in 5.1%, transaortic approach in 7.4%, and subclavian approach in 0.9%. Device success rate was 95.6% (369 of 386) for patients with no MAC compared with 94.9% (356 of 375) for patients with MAC (P = 0.67). Total fluoroscopy time and total contrast used were similar between groups. There were similar rates of post-procedural PVR and aortic valve gradients in patients with and without MAC ( Table 2 ). 
Mortality and major complications
Thirty-day clinical follow up was available for all patients. Thirty-day mortality and major complications were similar between patients with and without MAC ( Table 3) . NYHA functional class improvement of one grade or more was similar between groups (87.3% vs. 89.1% vs. 91.7% for the no MAC, non-severe MAC, and severe MAC, respectively; P = 0.62). There were 10/386 (2.6%, 1.42 14 .04 (log-rank P = 0.02 for severe vs. no MAC). Kaplan-Meier all-cause survival analysis was performed for both groups up to 36 months after TAVR. There was similar survival between patients with and without MAC (P = 0.13, log-rank test; Figure 3A ). Sub-group comparison showed that patients with nonsevere (mild or moderate) MAC had similar mortality to patients with no MAC, while patients with severe MAC had increased mortality (P = 0.046, log-rank test; Figure 3B , see Supplementary material on line, Figure S1 ).
Multivariable analyses were performed to evaluate the independent effect of MAC on overall and 1-year mortality and cardiovascular mortality. Overall, there were 207 deaths (mortality event rate 151.8 per 1000 person-years, 95% CI 132.5-173.9) among the 761 patients Figure) . A univariable and multivariable analysis of predictors for new PPI was performed ( 
Mitral valve disease
Pre-TAVR MR distribution was similar between groups ( Table 1) . Overall, improvement of one grade or more in MR between patients with and without MAC was similar (31.0% vs. 32.5% respectively, P = 0.70). Sub-group analysis revealed that 33.2% of patients with non-severe MAC had one grade or more MR improvement vs. 22 .0% of patients with severe MAC (P = 0.14 for severe MAC vs. no MAC). MR improvement was not associated with 1-year or with overall mortality (1-year mortality: OR 0.67, 95% CI 0.32-1.40, P = 0.29; overall mortality: HR 0.86, 95% CI 0.58-1.29, P = 0.47). Patients with severe MAC had reduction in pulmonary artery systolic pressure (PASP) from 44.5 ± 15 mmHg to 40.5 ± 12 mmHg before and after TAVR, respectively. Patients with no MAC had reduction in PASP from 39.8 ± 15 mmHg to 34.9 ± 13 mmHg before and after TAVR, respectively. Pre-and post-TAVR gradients >10 mmHg were found in one patient with no MAC (0.26%), one patient with non-severe MAC (0.33%) and five patients with severe MAC (6.9%). Postprocedural mitral valve gradient > _5 mmHg was found in 3.5% of the patients without MAC vs. 22 .5% of the patients with MAC (P < 0.001). In the severe MAC sub-group, 50.7% had gradient > _5 mmHg vs. 15 .9% in the non-severe MAC sub-group (P < 0.001). Postprocedural mitral valve gradient > _5 mmHg was not associated with overall mortality (HR 0.93, 95% CI 0.61-1.43, P = 0.75).
Discussion
Degenerative calcification of the mitral annulus is accelerated by conditions that increase mitral valve stress such as aortic valve stenosis. 1, 20 Nonetheless, there is limited data on the prevalence of MAC among patients with severe AS and its influence on clinical outcomes following TAVR. The results of the present study indicate that half of the patients with severe AS evaluated for TAVR were found to have at least some degree of MAC in pre-TAVR cardiac CT. Severe MAC, defined as calcification in more than half of the mitral annulus circumference was found in 10% of the entire cohort. Similar short and midterm clinical outcomes were found in patients with and without MAC, but severe MAC was a strong independent predictor of allcause and cardiovascular mortality and of new PPI following TAVR.
Severe MAC was also found to be strongly associated with significant gradient (> _5 mmHg) across the mitral valve post-TAVR. The association between MAC and calcific AS was first established in 1954 by Simon and Liu, 21 who found AS in 27% of 59 autopsy specimens of patients with MAC. In a retrospective evaluation of echocardiograms, Movahed et al. 6 noted that MAC was present in 15% of patients with AS compared with only 6% of patients without AS. The prevalence of echocardiography diagnosed MAC was found to be 23% in 219 patients with mild to moderate AS. 22 A recent study examining CT scans of 106 patients with severe AS that underwent aortic valve replacement showed evidence of MAC in 53% of the patients. 16 The present study included a relatively large cohort of patient with severe AS (761 patients). It demonstrated MAC to be prevalent in 49.3% of the cases. Severity of MAC classified with pre-TAVR CT scans was mild in 30.4%, moderate in 9.5% and severe in 9.5%. Increased mitral valve stress is the underlying mechanism contributing to this high prevalence of MAC among a population of elder patients with severe AS and hypertension. 1 It is mediated by increased left ventricular peak systolic pressure and therefore increased mitral valve closing pressure resulting in excess annular tension and subsequently annulus degeneration. Few previous studies have demonstrated correlation between MAC and increased cardiovascular and all-cause mortality. 4, 23, 24 Fox et al. examined the association between MAC assessed by echocardiography and the incidence of cardiovascular death and all-cause death among 169 subjects with MAC vs. 1028 subjects without MAC over 16 years of follow-up. 4 In multivariable adjustment for traditional cardiovascular risk factors, MAC was associated with an increased risk cardiovascular death (HR- 1.6 ) and all-cause death (HR- 1.3) . Similar findings were demonstrated by Ramaraj et al. during 12 years of follow-up. 24 In the present cohort of patients with severe AS, MAC (including all grades of severity) was not found to increase mortality during a mean follow-up period of less than 2 years. Nonetheless, utilizing CT for MAC assessment and sub-dividing the patients according to MAC severity have enabled to recognize a strong independent correlation between severe MAC and mortality (both all-cause and cardiovascular) following TAVR. In both analyses of overall mortality up to 3-years and of 1-year mortality, severe MAC was determined to be a strong predictor of death and of cardiovascular death following this procedure ( Figures 3B and 4 , Table 4 and Supplementary ma terial online, Table S1 ). Possible explanations for these findings are that MAC may be a marker for atherosclerotic disease burden and for end-organ damage or that other unmeasured factors such as metabolic, inflammatory and haemostatic risk factors might be responsible for the increase risk of mortality in patients with MAC and severe AS following TAVR. MAC generally has little or no impact on left ventricular inflow or mitral valve function because unlike in rheumatic mitral involvement, there is usual sparing of the leaflet commissures in these patients. 1 Nonetheless, severe calcification of the mitral annulus may occasionally cause MR or stenosis. 6, 25 Movahed et al. examined 24 380 echocardiograms and found MAC to be present in 11.7% of patients with MR vs. 4 .3% without MR. 6 A possible mechanism for this association is that calcium infiltration of the base of the posterior leaflet reduces leaflet mobility, increases traction on the chordae and elevates the leaflets, which facilitates chordal elongation or rupture, causing secondary MR. In a small study of 35 patients, Durst et al. 26 found MAC with encroaching onto the leaflets and restricting leaflet motion to be associated with a reduction in MR improvement after TAVR. In our current analysis, pre-TAVR MR distribution was similar between groups and improvement of one grade or more in MR between patients with and without MAC was similar at 1-month echocardiography follow-up. Longer-term follow-up may be needed to demonstrate changes in MR improvement rates following this procedure. Interestingly, the present study revealed a strong association between MAC and significant gradients across the mitral valve. Half of the patients with severe MAC had at least 5 mmHg post-TAVR mitral valve gradient. Previously, the existence of significant mitral valve gradient in patients with MAC was reported to be rare. 1, 25, 27 Nonetheless, when MAC is extensive it may invade the inter-annular fibrosa and limit leaflets mobility. It should be highlighted, that with the current follow-up period, we could not demonstrate association between post-TAVR significant mitral valve gradient and mortality. Nonetheless, a careful assessment of mitral valve stenosis severity and post-TAVR symptomatic status may help to identify a subset of patients that can benefit from mitral valve intervention after TAVR.
Examining the short-term effect of MAC on the clinical outcomes after TAVR revealed no correlation between MAC and 30-day mortality or major complications. Nonetheless, severe MAC was found to be a strong predictor of new PPI following TAVR (OR 2.83, Table 5 ). Self-expandable valve implantation and pre-procedural right bundle branch block are both strong predictors for new PPI following TAVR in the present cohort as well as in previous reports. 28 MAC was previously found to be related to new PPI after TAVR in one relatively small cohort of patients that had self-expandable valve implantations. 29 In an analysis of 105 patients, Boerlage-Van Dijk et al. found
MAC (OR 1.3) and preexisting right bundle branch block (OR 8.5) as independent predictors for PPI after TAVR. The association between MAC and conduction system abnormalities was noted in the earliest reports of this entity. 1 Patients with MAC have higher prevalence of atrioventricular block, bundle branch block and intra-ventricular conduction delay. Higher incidence of conduction disease may be due to direct extension of calcific deposits to the region of the atrioventricular node and the bundle of His or due to diffuse degenerative conduction system disease that is frequently associated with MAC. 1, 30 The trauma inflicted by the valve stent frame and by the valvuloplasty balloon during pre or post-dilatation and during valve deployment is more likely to result in a high degree atrioventricular block in patients with severe MAC as demonstrated in the current analysis.
Study limitations
A main limitation of the present study is that it represents a retrospective, single-center experience with a limited follow-up period. The sub-group of patients with severe MAC was relatively small and likely had high degree of confounding. Nonetheless, despite the fact that half of the patients with severe AS have MAC, previous studies that examined predictors of mortality and clinical outcome for these patients did not include MAC in their analysis. Future multi-center studies with larger number of patients and longer follow-up may further clarify this subject. Although severe MAC was found to be a strong predictor of all-cause mortality in the present study, the mechanism attributing to these results could not be determined.
Conclusion
Half of the patients with severe AS evaluated for TAVR were found to have MAC. Severe MAC is a strong predictor of all-cause and cardiovascular mortality and of conduction abnormalities following TAVR and should be included in future risk stratification models for TAVR. Severe MAC is associated with significant gradient across the mitral valve.
Clinical perspective
There is limited data on the prevalence of MAC among patients with severe AS and its influence on clinical outcomes following TAVR.
Our data suggest that half of the patients with severe AS evaluated for TAVR have at least some degree of MAC in pre-TAVR cardiac CT. A subset of patients with concomitantly severe MAC and AS has increased risk for mortality and conduction abnormalities following TAVR. Future studies are needed to determine if patients with severe MAC and AS may benefit from earlier intervention and from lower threshold for PPI during follow-up after TAVR.
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